Chronic rejection of major histocompatibility complex class II-disparate skin grafts after anti-CD3 therapy: A model of antibody-independent transplant vasculopathy

Transplantation

Volumn 66, Issue 11, 1998, Pages 1537-1544

  Le Moine, Alain ^a   Flamand, Véronique ^a   Noël, Jean Christophe ^a   Fayt, Isabelle ^a   Goldman, Michel ^a   Abramowicz, Daniel ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN FIBROSIS; SKIN GRAFT;

ANIMALS; ANTIBODIES; ANTIGENS, CD3; CHRONIC DISEASE; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOGLOBULINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SKIN TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; VASCULAR DISEASES;

EID: 0032535746     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812150-00019     Document Type: Article

References (39)

1. Gjertson D. Multifactorial analysis of renal transplants reported to the United Network for Organ Sharing Registry. In: Terasaki P, Cecka M, eds. Clinical transplants 1992. Los Angeles: UCLA Tissue Typing Laboratory 1993; 299.
2. Geraghty JG, Stoltenberg RL, Sollinger HW, Hullett DA. Vascular smooth muscle cells and neointimal hyperplasia in chronic transplant rejection. Transplantation 1996; 62: 502.
3. Stoltenberg RL, Geraghty J, Steele DM, Kennedy E, Hullett DA, Sollinger HW. Inhibition of intimai hyperplasia in rat aortic allografts with cyclosporine. Transplantation 1995; 60: 993.
4. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. I. Time course and immunogenetic and immunopathological considerations. Am J Pathol 1994; 144: 260.
5. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. III. Effects of recipient treatment with a monoclonal antibody to interferon-γ. Transplantation 1994; 57: 1367.
6. Nagano H, Mitchell RN, Taylor MK, Hasegawa S, Tilney NL, Libby P. Interferon-γ deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1997; 100: 550.
7. Kitamura D, Roes J, Kuhn R, Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 1991; 350: 423.
8. Billingham R, Medawar PB. The technique of free skin grafting in mammals. J Exp Biol 1951; 28: 385.
9. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1987; 84: 1374.
10. Rosenberg AS, Finbloom DS, Maniero TG, Van der Meide PH, Singer A. Specific prolongation of MHC class II disparate skin allografts by in vivo administration of anti-IFN-γ monoclonal antibody. J Immunol 1990; 144: 4648.
11. Rosenberg AS, Singer A. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu Rev Immunol 1992; 10: 333.
12. Hirsch R, Gress RE, Pluznik DH, Eckhaus M, Bluestone JA. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol 1989; 142: 737.
13. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 1994; 152: 5135.
14. Russell PS, Chase CM, Colvin RB. Alloantibody and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis. Transplantation 1997; 64: 1531.
15. Orosz CG, Pelletier RP. Chronic remodeling pathology in grafts. Curr Opin Immunol 1997; 9: 676.
16. Armstrong AT, Strauch AR, Starling RC, Sedmak DD, Orosz CG. Morphometric analysis of neointimal formation in murine cardiac allografts. Transplantation 1997; 63: 941.
17. Dvorak HF, Mihm MC, Jr., Dvorak Am, Barnes BA, Manseau EJ, Galli SJ. Rejection of first-set skin allografts in man: the microvasculature is the critical target of the immune response. J Exp Med 1979; 150: 322.
18. Nolan CR, Saenz KP, Thomas CAI, Murphy KD. Role of the eosinophil in chronic vascular rejection of renal allografts. Am J Kidney Dis 1995; 26: 634.
19. Shi C, Lee WS, He Q, et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci USA 1996; 93: 4051.
20. Wood PJ, Roberts IS, Yang CP, Cossens IA, Bell EB. Prevention of chronic rejection by donor-specific blood transfusion in a new model of chronic cardiac allograft rejection. Transplantation 1996; 61: 1440.
21. Reinke P, Schwinzer H, Hoflich C, et al. Selective in vivo deletion of alloactivated TH1 cells by OKT3 monoclonal antibody in acute rejection. Immunol Lett 1997; 57: 151.
22. Smith JA, Bluestone JA. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Curr Opin Immunol 1996; 9: 676.
23. Esser MT, Dinglasan RD, Krishnamurthy B, Gullo CA, Graham MB, Braciale VL. IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones. J Immunol 1997; 158: 5612.
24. Del Prete GF, De Carli M, Ricci M, Romagnani S. Helper activity for immunoglobulin synthesis of T helper type 1 (Th1) and Th2 human T cell clones: the help of Th1 clones is limited by their cytolytic capacity. J Exp Med 1991; 174: 809.
25. Parronchi P, De Carli M, Manetti R, et al. IL-4 and IFN (α and δγ) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol 1992; 149: 2977.
26. Yagita H, Hanabuchi S, Asano Y, Tamura T, Nariuchi H, Okumura K. Fas-mediated cytotoxicity: a new immunoregulatory and pathogenic function of Th1 CD4+ T cells. Immunol Rev 1995; 146: 223.
27. Ramsdell F, Seaman MS, Miller RE, Picha KS, Kennedy MK, Lynch DH. Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int Immunol 1994; 6: 1545.
28. Hahn S, Gehri R, Erb P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev 1995; 146: 57.
29. Auchincloss H Jr, Sultan H. Antigen processing and presentation in transplantation. Curr Opin Immunol 1996; 8: 681.
30. Chow LH, Huh S, Jiang J, Zhong R, Pickering JG. Intimai thickening develops without humoral immunity in a mouse aortic allograft model of chronic vascular rejection. Circulation 1996; 94: 3079.
31. Martinez OM, Ascher NL, Ferrell L, et al. Evidence for a non-classical pathway of graft rejection involving interleukin 5 and eosinophils. Transplantation 1993; 55: 909.
32. de Groen PC, Kephart GM, Gleich GJ, Ludwig J. The eosinophil as an effector cell of the immune response during hepatic allograft rejection. Hepatology 1994; 20: 654.
33. Chan SY, DeBruyne LA, Goodman RE, Eichwald EJ, Bishop DK. In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection. Transplantation 1995; 59: 1155.
34. Kadin M, Butmarc J, Elovic A, Wong D. Eosinophils are the major source of transforming growth factor-β1 in nodular sclerosing Hodgkin's disease. Am J Pathol 1993; 142: 11.
35. Stouffer GA, Owens GK. TGF-β promotes proliferation of cultured SMC via both PDGF-AA-dependent and PDGF-AA-independent mechanisms. J Clin Invest 1994; 93: 2048.
36. Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol 1997; 17: 70.
37. Noguchi H, Kephart GM, Colby TV, Gleich GJ. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am J Pathol 1992; 140: 521.
38. Waki S, Uehara S, Kanbe K, Nariuch H, Suzuki M. Interferon-γ and the induction of protective IgG2a antibodies in non-lethal Plasmodium berghei infections of mice. Parasite Immunol 1995; 17: 503.
39. Snapper CM, Paul WE. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987; 236: 944.